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Objective: To examine the effect of recombinant human IL-10 (rhlL-10) on MAC infection of human macrophages and 
C57BU6 mice. 
Methods: We compared rhlL-10 with the effects of the immunosuppressive drugs prednisolone and cyclosporin A, both 
in vitro and in  vivo. 
Results: There was no effect of rhlL-10 on the multiplication of MAC in human macrophages after 1 week of infection. 
In C57BU6 mice, rhlL-10 at 2.5 or 25 pg/mouse had no additional rnultiplicatory effect after 3 weeks of infection, while 
the spleens of mice treated with prednisolone had 600% higher bacteria than controls or rhlL-10-treated mice (p<O.Ol). 
Conclusions: These data suggest that rhlL-10 does not further decrease the resistance of human macrophages and 
C57BL/6 mice to MAC infection, whereas prednisolone leads to increased multiplication of MAC in the spleens of infected 
C57BL/6 mice. These results may be of interest in the context of the therapeutic use of rhlL-10 in some autoimmune 
disorders. 
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INTRODUCTION 
Human interleuhn-10 (IL-10) is a cytokine which 
plays a pivotal role in immune response regulation. It is 
produced mainly by monocytes/macrophages and Th2 
lymphocytes [ 1-31 and inhlbits monocyte/macrophage 
functions, notably monocyte proliferation, macrophage 
phagocytosis, antigen presentation, expression of MHC- 
11, and production of cytokines such as interferon-?, 
GM-CSF, TNF, LT, IL-la, IL-3, and IL-6. It decreases 
microbicidal activity by reducing the respiratory burst 
and the NO production in macrophages, and dimi- 
nishes monocyte-dependent T-cell proliferation and 
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effector functions [4-11]. These effects have been 
partially confirmed in vivo, suggesting a beneficial 
effect of IL-10 in murine septic shock models and 
autoimmune-mediated diseases [12-141. This immuno- 
suppressive effect of IL-10 has therapeutic interest in 
the treatment of human conditions with uncontrolled 
or excessive immune response, such as T-cell-mediated 
autoimmune diseases, transplant rejection, and @- 
versus-host reaction, or TNF-mediated diseases, such 
as systemic inflammatory response syndrome (SIRS). 
Nevertheless, therapy with IL-10 might simultaneously 
have a deleterious effect by favoring concomitant 
infections that require intact macrophage functions. We 
therefore investigated the effects of exogenous IL-10 in 
an infection with an intracellular pathogen. Myco- 
bacterium avium complex (MAC) consists of primarily 
intracellular bacteria which multiply within phagocytic 
cells. It is a frequently observed pathogen in AIDS- 
associated infections [ 15,161. Bermudez and Champsi 
[17] and Denis and Ghadirian [18] indirectly demon- 
strated a proinhibitory effect of IL-10 in vim and in 
vivo: mice as well as isolated murine macrophages 
infected with MAC produced IL-10; and increased 
560 
Geerdes-Fenge et  a l :  IL -10  and exper imenta l  M. aviurn complex infect ion 561 
mycobacterial clearance or survival was observed after 
the administration of anti-IL-10 antibodies. 
The aim of the present study was to evaluate the 
direct effect of IL-10 on the multiplication of MAC in 
vitro in human macrophages and in vivo in a mouse 
model. In one mouse experiment, we compared the 
effects of IL-10 with the eEects of corticosteroids and 
cyclosporin A, both potent immunosuppressive agents 
responsible for decreased resistance to intracellular 
pathogens. 
MATERIALS AND METHODS 
Bacteria 
Two strains of Mycobacterium avium complex from our 
own culture collection, MO-1 and LV-2, originally 
isolated from AIDS patients, were established and used 
in our previous studies [19-231. Pathogenicity of both 
strains was conserved by yearly infection of C57BL/6 
mice, and subsequent culture of infected spleens 
on 7H11 mycobacterial agar supplemented with 
Middlebrook OADC enrichment (Difco Laboratories, 
Detroit, Michigan, USA). One flat, transparent colony 
of each strain was picked and cultivated at 37°C in 
mycobacterial 7H9 broth (Difco) supplemented with 
Middlebrook ADC enrichment (Difco) in Falcon 
tissue-culture flasks (Becton Dickinson Labware, 
Oxnard, California, USA). After 30 days of culture, 
aliquots of the bacterial suspension were frozen at 
-80°C, and triple counts of colony-forming units 
(CFU) on 7Hl l  agar correlated the densities to 
1.8X108 CFU/mL for MO-1 and 1.9X1OS CFU/mL 
for LV-2. Before infection of macrophage monolayers 
or mice, the bacterial suspension was vortex agitated for 
1 min to avoid clumping. 
Drugs 
Recombinant human IL-10 (rhIL-10) was provided by 
Schering-Plough Research Institute (Kenilworth, NJ, 
USA). This molecule is active in the murine system, 
while murine IL-10 is not active in humans [5,7,11]. 
According to the manufacturer's instructions, the 
solution of rhIL-10 was diluted for the first mouse 
experiment with Tris buffer 10 mM, pH 7.4, aliquoted 
and frozen at -80OC. For the second mouse experi- 
ment, the solution was diluted in PBS without calcium 
and magnesium (Dulbecco) containing 1 mg/mL of 
murine serum albumin (Sigma-Aldrich, Saint- 
Quentin-en-Yvelines). PBS containing 10% normal 
human pool serum was used as solvent for the 
macrophage assay. Aliquots for daily usage were frozen 
at -80°C. Functional tests of these aliquots to assure 
activity were kindly performed by L. Hurlburt 
(Schering Plough Research Institute). The bioassay was 
based on stimulation of proliferation of MC/9 cells, a 
mouse mast cell line. Cells were incubated for 48 h 
with standard ddutions of a known quantity of IL-10 
and dilutions of the frozen aliquots. Proliferation was 
measured by spectrophotometric analysis. The final 
concentration in the unti-ozen aliquots was determined 
by comparing the dilution yielding 50% maximal 
stimulation with the dilution of the standard IL-10 
preparation yieldmg 50% maximal stimulation. The 
concentration and activity in the aliquots were 
confirmed. 
Prednisolone 21-sodium succinate purchased fi-om 
Sigma-Aldrich (Saint-Quentin, France) was diluted 
in PBS buffer to a concentration of 2.678 mg/mL, 
corresponding to a concentration of 2 m g / d  of 
prednisolone. Aliquots for daily usage were frozen at 
-20°C. For the macrophage assays, hrther dilutions 
were performed in the medium directly before use. 
Cyclosporin A was generously provided by Sandoz 
(Rueil-Malmaison, France). The powder was dduted in 
four parts ethanol and one part Tween to a concen- 
tration of 20 mg/mL. This stock solution was kept at 
4"C, and dilutions with normal sterile saline 1:lO were 
done immediately prior to use. 
The macrophage model 
The model has been described in our previous studies 
[19,21,22]. Briefly, human peripheral blood monocytes 
were obtained from healthy donors. Sixty milliliters of 
heparinized peripheral blood was mixed with 30 mL of 
RPMI 1640 tissue-culture medium (GIBCO BRL 
Laboratories, Grand Island, Ny, USA). This suspension 
was centrifuged on Ficoll-Paque (Pharmacia, Saint- 
Quentin-en-Yvelines, France) to obtain mononuclear 
leukocytes. These cells were washed twice in RPMI 
1640 medium, and monocytes were counted by an 
esterase stain method [24]. The cell suspension was 
distributed into Lab-Tek chambers (Miles Scientific, 
Div. Miles Laboratories, Inc., Naperville, Ill, USA) to 
obtain 5 X lo5 monocytes per chamber. After sedimen- 
tation for 3 h at 37°C in a 5% CO:! atmosphere with 
100% humidity, the super-natant containing non- 
adherent cells was removed, and adherent cells corres- 
ponding to monocytes were incubated in RPMI 1640 
medium containing 10% of pooled human normal 
serum. This nutrient medium was changed on days 2 
and 4 after rinsing the chambers with RPMI. On  day 
7, a homogeneous monolayer of macrophages was 
obtained. Viability was 99% as tested by the trypan blue 
exclusion test. 
Infection of macrophage monolayers 
For the inoculum, an aliquot of the frozen suspension 
of MAC was thawed at room temperature and diluted 
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with RPMI 1640 tissue-culture medium containing 
10% of pooled human normal serum, to obtain a 
concentration of 3 X lo6 CFU/mL. Macrophages were 
inoculated on day 7 of culture with 1 mL of this sus- 
pension and incubated for 60 min at 37OC in a 5% COa 
atmosphere with 100% humidity. After ingestion, the 
remaining extracellular bacteria were removed by four 
washings with 2 mL of RPMI each. To control the 
number of intracellular bacteria at this time, three 
chambers of macrophages were lysed with d d l e d  
water, serial dilutions were plated on agar, and CFUs 
were counted after 14 days of culture. 
To the other chambers, fiesh medium and rhIL-10 
were added at different concentrations. Controls with 
only medmm were established. The macrophages were 
then incubated again at 37OC in a 5% COz atmosphere. 
On  day 4 after inoculation, the intracellular and super- 
natant mycobacteria were counted separately in half of 
the chambers. Serial dilutions of the supernatants or the 
lysed macrophages were plated on 7 H l l  agar sup- 
plemented with OADC enrichment. To the remaining 
wells, new media plus the respective rhIL-10 concen- 
trations were added. On day 7, the intracellular and 
supernatant mycobacteria were cultured separately. 
After 10-14 days of culture at 37"C, colonies were 
counted, and the number of CFUs per chamber was 
calculated. An average of 10% of the macrophages 
infected with MO-1 and 13% of those infected with 
LV-2 ruptured or detached in every experimental 
group. By observing any changes in the intensity of the 
monolayers over time, we determined that there was no 
preferential detachment of infected macrophages or 
cytokine-stimulated macrophages from the surface of 
the slides. 
Expression of CFU counts 
In this model, the multiplication of mycobacteria is 
mainly intracellular [25]. As in our previous studies, the 
bacterial load of macrophages that detached fiom the 
chambers and remained in the supernatant was counted 
with the extracellular bacteria. Thus, the total multi- 
plication of bacteria on day 4 was expressed by adding 
intracellular and supernatant CFU counts on day 4. 
Since supernatant bacteria were removed from the 
chambers on day 4 to replace the medium, the total 
multiplication of bacteria on day 7 was expressed by 
adding intracellular and supernatant CFU counts on 
day 7 plus supernatant CFU counts on day 4. Two 
experiments with triple determination were carried 
mice. Female normal C57BL/6 mice (7-8 weeks old) 
(Iffa Credo, L'Arbresle, RhGne, France) with an average 
body weight of 2 0 g  were used after 1 week of 
quarantine. These animals develop chronic MAC 
infection without spontaneous mortality. In the first 
experiment (low inoculum size), two groups of 12 mice 
each were pretreated subcutaneously with 0.2 mL of 
rhIL-10 at 125 pg/kg per day over 3 days (days -3 to 
- l), and two other groups served as controls and were 
injected with 0.2 mL of Tris buffer 10 mM. On day 0, 
one treatment group and its control group were 
infected by the intravenous route into the retroorbital 
plexus with a 0.1 mL suspension of MAC containing 
10' CFU, and the other group and its control were 
infected with lo3 CFU. The inoculum size was verified 
by inoculation on agar. Treatment was continued each 
day through day 21. Treated and control mice were 
killed at days 7,14 and 21 after the infection, 24 h after 
the last injection of drugs. Four randomly selected 
animals were sacrificed at each time point. 
In the second experiment @gh inoculum, com- 
parison of rhIL-10, cyclosporin A, and prednisolone), 
four groups of 12 mice each were pretreated sub- 
cutaneously over 3 days (days -3 to -1) with the 
immunosuppressant agents rhIL-10 (125 pg/kg per day 
in 0.1 mL), rhIL-10 (1.25 mg/kg per day in 0.1 mL), 
cyclosporin A (20rnglkg per day in 0.2mL), or 
prednisolone (20 mg/kg per day in 0.2 mL). Three 
groups of 16 mice each served as control groups and 
were pretreated with the same quantity of the respective 
solvents. On  day 0, an acute infection was established 
in all groups by injection of 1 X lo7 CFU of M. avium. 
The injection with the drugs or the solvents was 
continued each day for 21 days. Control mice were 
killed at day 1 after the infection to establish the initial 
inoculum size. Treated mice and control mice were 
lulled at days 7, 14 and 21 of treatment, 24 h after the 
last injection of drugs. Four randomly selected animals 
were sacrificed at each time point. 
Quantification of mycobacteria in spleen and lung 
The spleen and the right lung of each mouse were 
removed aseptically, weighed and homogenized in 
1 mL of sterile water with a glass homogenizer. Serial 
10-fold dilutions were plated onto 7 H l l  agar (Difco) 
supplemented with OADC enrichment (Difco). After 
14 days at 37OC, colonies were counted, and the 
number of CFUs was calculated per gram of tissue. 
out for each strain at each concentration. 
The mouse model 
As in our previous studies [20,23,26,27], we assessed a 
model of acute infection with MAC (strain MO-1) in 
Statistical analysis 
Results of CFU counts in control experiments and 
drug experiments were compared day by day by a 
parametric one-way analysis of variance. If the F value 
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Figure 1 CFU/g of spleen of IL-10-treated mice and controls in C57BL/6 mice infected with lo2 or lo3 CFU of MAC 
(mean of four mice at each time point5D). 
was significant, a multiple comparison post-test was 
carried out. Significance was defined as p<0.05. 
RESULTS 
We tested the effect of rhIL-10 on the multiplication 
of two different strains of MAC in human macro- 
phages. With strain MO-1, there were no significant 
differences in multiplication of MAC at days 4 and 7 
between treated and untreated macrophages (log CFU/ 
chamber on day 7: rhIL-10 0.05 n g / d ,  5.22e0.11; 
0.5 ng/mL, 5.28k0.06; 10 ng/mL, 5.15k0.03; and 
100 ng/mL, 5.27k0.02) compared to the control (5.28 
k0.04). Similar results were obtained with strain LV-2 
(log CFU/chamber on day 7: rhIL-10 10 ng/mL, 
6.0620.1 1; 100 n g / d  5.97k0.03; control, 6.19 
e 0.1 2). 
We then examined the effect of rhIL-10 in vivo on 
the susceptibility of C57/BL6 mice to the inoculation 
with low quantities of lo2 and lo3 MAC per mouse. 
The treatment with rhIL-10 (125 pg/kg per day) did 
not cause significant differences. As shown in Figure 1, 
there was even a slightly lower concentration of CFU 
per gram spleen in the rhIL-10-treated mice than in the 
controls. There were no significant differences between 
the spleen weights of all groups. As expected from 
earlier experiments with low inoculum sizes, there was 
no growth of MAC in the lungs of the control groups 
or in the rhIL-10-treated groups. 
We then compared the effect of rhlL-10 on the 
development of M. avium infection with the effects of 
prednisolone and cyclosporin A (Figure 2). In the three 
control groups having received the respective solvents, 
there was no significant difference at 3 weeks of 
infection (log CFU/g of spleen at day 7: PBS alone, 
7.48k0.22; PBS containing MSA, 7.37&0.15; and 
PBS with 8% ethanol and 2% Tween, 7.61k0.05). 
Treatment with rhIL-10 at 125 pg/kg per day 
(7.46k0.4) and at 1.25 mg/kg per day (7.61 k0.06) did 
not cause significant differences in the concentrations 
of MAC in spleen or lung compared to the control 
groups. The prednisolone-treated mice developed 
infection with significantly higher concentrations of 
MAC in the spleens (8.25k0.25) than the control 
groups and than the rhIL-10-treated mice (p<O.Ol);  
the difference from the cyclosporin-treated group was 
not significant. 
The cyclosporin-treated group had higher CFU/g 
of spleen (7.83k0.08) than the control and rhIL-10 
groups but the difference was not significant. There was 
no significant difference between the CFU counts in 
the lungs of all groups. As expected, the spleen weights 
of the prednisolone-treated mice were significantly 
lower than those of the other groups (204225 mg 
versus 445f77 mg, ~ ~ 0 . 0 1 ) .  Therefore, the usual 
notation of CFU/g of organ could have given too high 
numbers in the prednisolone group due to the lower 
spleen weight. We therefore also analyzed the absolute 
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Figure 2 CFU/g of spleen of C57BL/6 mice infected with lo7 CFU of MAC after daily treatment with IL-10, cyclosporin 
A, or prednisolone (mean of four mice at each time pointkSD). 
number of CFU per whole organ, and confirmed a 
significantly higher count of CFU/spleen in the 
prednisolone group compared to the control groups 
with PBS and PBS with MSA, and to the rhIL-10 
group with the lower rhIL-10 concentration of 
125 pg/kg per day (p<0.05). 
DISCUSSION 
The intensity of MAC infection is closely related to 
cytokine activity. There is evidence that infection with 
MAC in vitro and in vivo causes release of IL-1, IL-6, 
TNF, TGF-P, and IL-10 [17,18,28-311. In vitro and in 
vivo experiments have indicated a mycobacteriostatic 
role of TNF, IL-2 and GM-CSF in murine and human 
macrophages and in mice [32,33]. Therefore, treatment 
with IL-10 could possibly enhance infection with M. 
avium via antagonism with these pro-inflammatory 
cytokines. 
Bermudez and Champsi [17] and Denis and 
Ghadirian [18] demonstrated the role of endogenous 
IL-10 in MAC infection in murine macrophages in 
vitro and in mice in vivo. Denis and Ghadirian [18] 
found increased production of IL-10 by MAC-infected 
murine macrophages, and enhanced mycobacteriostatic 
activity, after the addition of anti-IL-10 antibodies to 
the supernatants. Bermudez and Champsi [17] studied 
the effects of murine IL-10 on the survival of MAC in 
murine peritoneal macrophages. The addtion of IL-10 
to the supernatants of infected macrophages led to 
inhibition of the mycobacteriostatic effects of TNF and 
of GM-CSF, while IL-10 alone did not change the 
number of CFU/mL compared to the control. In our 
study, there was similarly no direct effect of additional 
exogenous rhIL-10 on the multiplication of MAC in 
human macrophages in vitro; however, we did not 
assess the interactions with TNF or GM-CSE 
Both Bermudez and Champsi and Denis and 
Ghadn-ian indirectly demonstrated an inhibitory effect 
of IL-10 in vivo: mice infected with MAC produced 
higher amounts of IL-10, and increased survival was 
observed after the administration of anti-IL-10 anti- 
bodies. In our study, we assessed the effect of rhIL-10 
on murine MAC infection. Several other study groups 
connected to our group used the same lot of IL-10 
and found positive effects of IL-10 [34-361. The daily 
administration of rhIL-10 (2.5 and 25 pg per mouse) 
was similar to or even exceeded the concentrations 
that were effective in suppressing endotoxin- or 
exotoxin-mediated shock [12,13] or delayed-type 
hypersensitivity [37] in mice. These concentrations 
had no effect either on the susceptibility to a low 
inoculum size or on the course of an established MAC 
infection, while the immunosuppressive drug pred- 
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nisolone, and to a lesser degree also cyclosporin A, led 
to increased multiplication of MAC in the spleens of 
infected mice. 
The dose of prednisolone (20 mg/kg per day) was 
similar to dosages that were effective in murine idam-  
matory models in preventing experimental immuno- 
logic liver injury, the production of pro-inflammatory 
cytokines, and the development of granuloma [3840]. 
The significant increase in the MAC load that we 
observed in the spleens corresponds to results of other 
studies that found facilitated infection with M.  para- 
tuberculosis or activation of spontaneous crypto- 
sporidiosis in mice with similar dosages [41,42]. 
Cyclosporin A at dosages of 15-22.5 mg/kg per 
day is effective in preventing rejection of heart trans- 
plantations in mouse transplantation models [43-451. In 
rats, adjuvant-induced arthritis was reduced at intra- 
peritoneal dosages of 5 or 20 mg/kg per day [46,47]. 
In a murine model of delayed-type hypersensitivity, 
granulomas were suppressed by oral cyclosporin A at 
50 and 100 mg/kg per day [39]. Our tested dosage of 
20 mg/kg per day cyclosporin A led to an increase of 
MAC in the spleens. However, this increase did not 
reach a significant level. While in Sprague-Dawley rats, 
a subcutaneous dose of 20 mg/kg four times per week 
was used to establish a model of disseminated MAC 
infection [48], other studies have shown a proinfectious 
potency only at higher dosages. Infection of BALB/c 
+/+ mice with Listeria monocytogenes was optimal with 
an oral dose of 95 mg/kg per day or an intramuscular 
dose of 375 mg/kg per day [49]. Oral treatment with 
40mg/kg per day was found to induce impaired 
resistance of ICR mice to localized Candida albicans 
thrush-like lesions, whereas systemic candidiasis was 
not affected by cyclosporin A [50]. Oral treatment with 
8 mg/kg per day of BALB/c mice was too low to 
increase an infection with M.  leprae compared with 
untreated mice [51]. In our model, the proinfectious 
effect of cyclosporin A was lower than that of predni- 
solone; however, the difference between these two 
groups was not significant either. 
Our data suggest that rhIL-10 at  the tested concen- 
trations has no additional permissive effect on the 
multiplication of MAC in human macrophages and 
C57BL/6 mice. This lesser proinfectious effect com- 
pared to prednisolone and cyclosporin A may be of 
interest in the context of the therapeutic use of rhIL- 
10 in some autoimmune disorders. 
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